Recommended Liver Monitoring for Tigecycline
Tigecycline, a glycylcycline antibiotic, carries a risk of elevated liver enzymes, prompting specific monitoring during therapy. Guidelines prioritize ALT (alanine aminotransferase) and AST (aspartate aminotransferase) as key tests, with bilirubin also recommended to detect potential hepatotoxicity early.[1][2]
Why These Tests During Tigecycline Treatment
Tigecycline's label notes reversible elevations in ALT and AST in up to 15-20% of patients, more common in those with hepatic impairment or prolonged use. These transaminases reflect hepatocellular injury, rising before symptoms appear. Bilirubin tracks cholestasis or severe damage. Baseline tests before starting therapy, then weekly during treatment (or more often in high-risk cases), catch issues promptly.[1][3]
Frequency and High-Risk Scenarios
- Standard schedule: Check ALT, AST, and total bilirubin at baseline, then every 7 days.[1]
- Adjust for risks: Daily or every 2-3 days if patient has liver disease, biliary obstruction, or concurrent hepatotoxins (e.g., other antibiotics, alcohol).[2]
- Duration matters: Risk peaks after 14 days; extend monitoring for courses beyond 14 days.[3]
What Happens If Tests Are Elevated
Mild rises (up to 3x upper limit of normal) often resolve without stopping therapy. Hold or discontinue if >5x ULN or with symptoms like jaundice/nausea. No specific reversal agent exists; supportive care applies.[1][2]
Alternatives If Liver Concerns Arise
Switch to drugs with lower hepatotoxicity like vancomycin or linezolid for skin/soft tissue infections. For intra-abdominal infections, consider ertapenem or piperacillin-tazobactam, monitoring their own liver profiles.[3]
FDA Labeling and Clinical Trial Data
Trials showed ALT elevations in 26% of tigecycline patients vs. 16% comparators; AST in 21% vs. 13%. Post-marketing reports include rare hepatitis. No dedicated liver-specific guidelines beyond label, but IDSA endorses transaminase tracking for tetracyclines generally.[1][2]
Sources
[1]: Tygacil (tigecycline) Prescribing Information - Pfizer
[2]: FDA Adverse Event Reporting - Tigecycline Hepatotoxicity
[3]: IDSA Guidelines on Complicated Infections